



METABOLIC CHANGES IN DIABETES MELLITUS

* Please check out <u>this link</u> to know if there are any changes or additions.

We advice to study **"physiology of** pancreas and insulin" & "Diabetes (pathology)" lectures before you start studying this lecture.

Revised by هشام الغفيلي & خولة العماري

Color index: Important | Doctors notes | Further explanation.

✓ Background

-Differences between type 1 and type 2 DM -Natural course of T1DM -Natural course of T2DM ✓ Diagnostic criteria for DM ✓ Metabolic changes in DM -Increase of hepatic glucose output -Decrease of glucose uptake -Inter-organ relationship in T1DM and T2DM ✓ Mechanisms of diabetic complications

COMPARISON BETWEEN TYPE 1 AND TYPE 2 DM

	Type I Diabetes:	Type II diabetes:			
Age of onset:	 Usually during childhood or puberty. Symptoms develop rapidly. 	 Frequently after age 35. Symptoms develop gradually. 			
Nutritional status at time of disease onset:	Frequently undernourished .	Obesity usually present. In the past, obesity was one of the risk factors but now it's considered as a cause.			
Prevalence:	< 10 %	> 90 %			
Genetic predisposition:	Moderate	Very strong. If one of an identical twins has type II diabetes then the other one is definitely gonna to develop it (eventually)			
Defect or deficiency:	Beta cells are destroyed (After being exposed to toxins), eliminating production of insulin.	Insulin resistance <u>combined with</u> inability of beta cells to produce appropriate quantities of insulin.			
Frequently of ketosis:	Common	Rare (insulin is still there> inhibition of ketosis)			
Plasma insulin:	Low to absent	High early in disease; low to absent in disease of long duration			
Acute Complications:	Ketoacidosis	Hyperosmolar coma (caused by high glucose levels)			
Treatment with oral hypoglycemic drugs:	UNresponsive.	Responsive.			
Treatment:	Insulin is always necessary.	Diet, exercise, OHG, insulin (may or may not be necessary), reduction of risk factors (weight reduction, smoking cessation, BP control, treatment of dyslipidemia) is essential to therapy.			




NATURAL COURSE OF T1DM

1- In normal people, the activity of insulin is 100% (all of beta cells are intact) \rightarrow a stimulus form the environment (e.g. a **viral infection**) triggers the process in people with genetic determinant that allows the β cells to be recognized as "nonself." (Law Andrew Law Andrew La

2- Over a period of years, this autoimmune attack on the β cells leads to gradual depletion of these cells \rightarrow decrease insulin secretion(Subclinical)


3- When 80% – 90% of the β cells have been destroyed \rightarrow the pancreas fails to respond adequately to ingestion of glucose, and symptoms suddenly appear (polyuria, polydipsia, polyphagia).





PROGRESSION OF T2DM

- First 10 years : obese people will develop a slight increment in glucose level with insulin resistance. Thus, the insulin secretion will increase as a <u>compensatory mechanism</u>.
- After this period of time and due to this hypersecretion; there will be a <u>decline in secretion</u> due to destruction of the β cells, and <u>dramatic increase in the glucose (126</u> mg/dL or higher).
- the insulin level will decline but won't be absent (it won't go lower than 10%, which is the level of insulin that keeps the adipose tissue taking up the glucose → prevent lipolysis and ketoacidosis).





CRITERIA FOR DIAGNOSIS OF DM

Test:	About test:	Increased risk for diabetes: (pre diabetic state)	Diagnosis of diabetes هنا نكون متأكدين أن المريض عنده سكر إذا ظهرت لنا أحد هذي النتائج	
2h in FPG:	Fasting is defined as no caloric intake for at least 8 h .*	5.6 - 6.9 mmol\L (IGF)	7 mmol\L	
OGTT on 75g:	2-hour plasma glucose during an OGTT. Test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.* يعطون الشخص 75 قرام جلوكوز ويقيسونه بعد ساعتين بالحالة النورمال الجلوكوز بيرتفع بعدين بيرجع نورمال ليش؟ لأن فيه هوميوستيسس اذا الشخص يعاني من مشاكل الجلوكوز ماراح يرجع نورمال	7.8 – 11 mmol\L (IGT)	11 mmol\L	
A1c:	The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay*	5.7 - 6.4% mmol\L	>= 6.5% mmol\L	
Random blood glucose	هنا نقيس مستوى الجلوكوز (عشوائيا) بدون تهيئة ظروف معينة "مانعطيهم جلوكوز من نفسه مرتفع" هالتست يستخدم لمن الشخص يجي ومعاه اعراض الهايبر جلايسيما الكلاسيكال	_	>= 11.1 mmol	
To convert from mmol\L to mg\dl use this equation: (mmol\L * 18 = mg\L) (القيم اللي حطيناها فقط بالميلي مول لتسهيل الحفظ! أغلب هذي الأرقام والمعلومات ماخذينها في الفيزيو، يعني المفروض انكم حافظينها خلاص :) of the past 2-3 months or not.				

of the past 2-3 months or not.


*In the absence of unequivocal hyperglycemia, they should be **conformed by repeat testing**.

FPG: Fasting plasma glucose || **IFG**: Impaired fasting glucose. || **PG**: post glucose. || **OGTT**: Oral glucose tolerance test. || **IGT**: Impaired glucose tolerance. **A1C**: Glycated hemoglobin. (HbA1C) || **DCCT**: diabetes control and complications test. || **NGSP**: National Glycohemoglobin Standardization Program.



HEMOGLOBIN A1C

- Hemoglobin A1C (A1C) is the result of <u>non-enzymatic</u> covalent glycosylation of hemoglobin.
- It is used to: estimate glycemic control in the last 3 months.
- A1C and fasting plasma glucose (FPG) were found to be <u>similarly effective</u> in diagnosing diabetes.





INTERTISSUE RELATIONSHIP IN T1DM

1-The intestine gives glucose, chylomicron and amino acids. In T1DM, there's **no insulin**, so the body use gluconeogenesis instead.


2- Amino acids enter the Kreps cycle in liver and go through gluconeogenesis to make glucose.
3- due to the lack of insulin, the adipose tissues can't use the glucose, thus they will go under

lipolysis and release <u>FAs</u> and <u>glycerol</u>.

4- **Glycerol** will be used in the gluconeogenesis, while **FAs** will enter the liver and – depending on the amount of FAs released- it will produce glucose also. Some of the FAs will give **ketone bodies** and some will turn into **triacylglycerol** and then **VLDL**.

5- **chylomicron** and **VLDL** usually get cleaved by <u>**lipoprotein lipase**</u>, but this enzyme needs <u>insulin</u> to work, so the VLDL and chylomicron will accumulate and HDL will decrease.


we can test cholesterol along with A1C and other tests to confirm the T1DM diagnosis).



Why we don't store all the glucose going to the liver? Insulin deficiency causes a drops in glucokinase and hexokinase levels \rightarrow so they can't trap glucose inside the liver.




INTERTISSUE RELATIONSHIP IN T2DM



نفس السلايد الماضي تقريبا، بس الفرق هنا عن تايب 1 أن هنا فيه انسولين (كمية قليلة) وبالتالي تمنع تكسر البروتينات والدهون. Remember the 10% we mentioned before that prevent proteolysis & lipolysis.



MAJOR METABOLIC CHANGES IN DM



METABOLIC EFFECTS OF DM

Absolute* or relative insulin deficiency leads to:**

↓ Glucose uptake

 \downarrow Glucose uptake by muscle & adipose tissue:

- Mechanisms of Decrease of Peripheral Glucose Uptake:
 - > In muscles:

□ ↓ Insulin → ↓ Glucose & amino acid uptake → ↑Protein breakdown → ↑Plasma glucose & amino acids.

- > Adipose Tissue
 - ↓ Insulin → ↓ Glucose uptake →
 ↑Plasma glucose.

† Glucose production

↑ Glucose production (from liver):


Mechanisms of Increase Hepatic Glucose Output

□ ↓ Insulin → ↓ Inhibitory effect on glucagon secretion → ↑Glucagon → ↑Gluconeogenesis & glycogenolysis in liver → ↑Plasma glucose.

*Absolute deficiency as in type I. **Relative deficiency as in type II.



TYPICAL PROGRESSION OF T2DM






GENERAL MECHANISMS FOR DIABETIC MICROVASCULAR COMPLICATIONS

Chronic hyperglycemia leads to:

- 1. ↑ Advanced Glycation End products (AGEs) of essential cellular proteins → cellular defects.
- 2. \uparrow Intracellular sorbitol \rightarrow \uparrow cell osmolality \rightarrow cellular swelling.
- 3. \uparrow Reactive Oxygen Species (ROS) \rightarrow oxidative stress \rightarrow cell damage.

1-ADVANCED GLYCOSYLATION END PRODUCTS (AGES)



2- SORBITOL METABOLISM: POLYOL PATHWAY

Polyol Pathway: A pathway in which glucose is metabolized to sorbitol within the cells by aldose reductase. This enzyme is present in all cells of the body.

Why it's metabolized to sorbitol? Due to the excess amount of glucose in blood (the body tries to reduce it).

***** The role of sorbitol in the pathogenesis of diabetic complications is


uncertain. Hypotheses are:


2- Sorbitol accumulation:

- A. Increase the intracellular osmotic pressure \rightarrow osmotic drag of fluid from extracellular space \rightarrow cell swelling.
- **B.** Alteration in the activity of PKC \rightarrow altered vascular endothelial factor (VEGF) activity \rightarrow altered vascular permeability.

In some tissues (seminal vesicles, ovaries and liver) there's an another enzyme that act on sorbitol, it's called sorbitol dehydrogenase. This enzyme's function is to convert sorbitol into fructose, which is in turn is needed for some biochemical reactions

in these tissues.







MICROVASCULAR COMPLICATIONS

	Diabetic Retinopathy	Diabetic Neuropathy	Diabetic Nephropathy
Definition:	A progressive microvascular complication of DM, affecting the retina of the eye.	Loss of both myelinated and unmyelinated nerve fibers.	Glomerular hyperfiltration → Microalbuminuria → Proteinuria & ↓ GFR → End-stage renal disease
Occurs in:	After 20 years of the disease: It's present in almost all T1DM & in 50 – 80% of <u>T2DM</u>	Both type 1 & type 2 DM	Both type 1 & type 2 DM.
Info. :	 Major cause of morbidity in DM (may lead to blindness) Its prevalence 1 with <u>increasing duration</u> of disease in both type 1 & 2 DM 	It correlates with the duration of DM & with glycemic control .	 ➤ The earliest clinical finding of diabetic nephropathy is microalbuminuria. ✓ Microalbuminuria: the persistent excretion of small amounts of albumin (30-300 mg per day) into the urine. ➤ Microalbuminuria is an important predictor of progression to proteinuria. ✓ Proteinuria: the persistent excretion of >300 mg albumin per day into the urine ➤ Once proteinuria appears, there is a steady ↓ in the glomerular filtration rate (GFR). ➤ Finally, end-stage renal disease occurs





Check your understanding!

Q1: Absolute or relative metabolic activity will affect?

- A. Lipid metabolism
- B. .CHO metabolism
- C. Protein metabolism
- D. All of the above

Q2: Sorbitol is converted to fructose by which enzyme?

- A. Aldose reductase
- B. Sorbitol dehydrogenase
- C. Sorbitol hydroxlyase
- D. Dglucokinase

Q3: the earliest clinical finding in diabetic nephropathy is :

- A. Microalbuminuria.
- B. Macroalbuminuria.
- C. Proteinuria.
- D. Albumin excretion is normal.

Q4: Testing the levels of which one of the following estimates glycemic control in the last 1-2 months : A. FBG B. .HBA1c C. FFA D. insulin

Q5: Regarding diabetic retinopathy, which one is incorrect:

A. Higher risk in type 1.B. Microvascular disease contributes in the progression

- of diabetic retinopathy.
- C. Never happens in type 2
- D. Common complication.

Q6:T1DM Is more strongly associated with Genetic than DMT2 :

- A. True
- B. False

1.D 2.B 3.A 4.B 5.C 6.B

Check your understanding!

Q7: In the beginning of Diabetic nephropathy the GFR will be ?

- A. Increased
- B. Decreased
- C. Normal
- D. Highly decreased

Q8: Which of the following is A major cause of morbidity in DM?

- A. Blindness
- B. end-stage renal disease
- C. infection
- D. None

Q9: mechanism of Diabetic microvascular complication :

- A. Increase intracellular sorbitol
- B. Increase cell osmolality
- C. Cellular swelling
- D. All of them

Q10:Chronic hyperglycemia will lead to non-enzymtic combination between excess glucose and amino acid in protein which is known as?

- A. Polyol pathway
- B. ROS
- C. Advanced glycosylation End product D. None of the above

Q11: Which one of the following cut-off points of hemoglobin A1C is used to diagnose diabetes?

A. Less than 6.5%B. More than 6.5%C. More than 5.6%D. Less than 5.6%

Q12: decrease in the lipolysis is a metabolic affect of insulin :

- A. True
- B. False

7.A 8.A 9.D 10.C 11.B 12.A



Done by:

- عبدالله الغزي.
- شهد العنزي.
- عبدالله الشنيغي.
 - لينا الشهري.
- أحمد الرويلي.
- نوف الرشيد.

(" 2) حين تنام وأنت تحتضن خيبة أملك لا تنس في الصباح أن توقظ أملك وتترك خيبتك نائمة

Resources:

- 435's slides and notes.

- Lippincott's illustrated reviews: Biochemistry – sixth edition.





@biochemteam435